Ketamine for OUD and Suicidal Ideation in the ED
NCT06111339
Recruiting
This is a pilot, double-blind, placebo-controlled randomized clinical trial of individuals with opioid use disorder (OUD) with suicidal ideation in the emergency department (ED) to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25). The primary aim is to evaluate the safety of the ketamine treatment. The secondary aim is to determine the preliminary efficacy of opioid- and suicide-related outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Opioid Use Disorder, Suicidal Ideation
Register for Updates
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
NCT04711005
Completed
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration. Standard safety, pharmacokinetics (PK) and qEEG monitoring will be evaluated at all dose levels. Subsequently, a 2-cohort multiple ascending dose (MAD) study will be conducted. Doses will be administered on days 1, 4, 8, and 11. Standard safety parameters will be monitored, and PK will be evaluated at all dose levels. Finally, a single-cohort gr... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/10/2024
Locations: Duke Early Phase Clinical Research, Durham, North Carolina
Conditions: Major Depressive Disorder
Register for Updates
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
NCT05414422
Completed
This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks \[Day -15 to Day -2\]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment \[Day 1\]), and post-treatment follow-up (7 and 14 days after infusion on Days 8 and 15, respectively). A total of 93 adult subjects with TRD will be randomly allocated in equal cohorts of 31 subjects/arm to the 3 arms of the study in a blinded manner.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/10/2024
Locations: Preferred Research Partners, Little Rock, Arkansas +20 locations
Conditions: Treatment Resistant Depression
Register for Updates
Prevention of Post Mastectomy With Intraoperative Ketamine
NCT03090776
Active Not Recruiting
Aim 1: To determine the effectiveness of perioperatively administered ketamine to decrease acute and persistent postmastectomy pain (PPMP). Hypothesis 1.1: Patients undergoing partial or total mastectomy treated with a bolus and perioperative infusion of the NMDA-receptor antagonist ketamine will have decreased postoperative pain and opioid utilization compared to those receiving saline control. Hypothesis 1.2: Patients undergoing partial or total mastectomy treated with a bolus and perioperat... Read More
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
05/02/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pain, Postoperative, Post-Mastectomy Chronic Pain Syndrome
Register for Updates
Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression
NCT02360280
Completed
About one-third of depressed patients will not get better after multiple antidepressant treatments. This situation put a high burden on patients with depression due to worsening quality of life and increasing health care costs. Difficult-to-treat depression might be even worse among Veterans given that the frequency of depressive symptoms is 2 to 5 times higher than among the general US population. A breakthrough discovery happened in recent years when investigators found that one infusion from... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Treatment-resistant Depression
Register for Updates
KAP for Depression in Abstinent Opioid Users
NCT05193318
Terminated
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks. Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks o... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/10/2024
Locations: Medical University of South Carolina Centerspace, Charleston, South Carolina
Conditions: Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
Register for Updates
Pain Medicine for Wound Care Procedures
NCT00701909
Completed
This is a randomized double-blind study to determine if the administration of a small-dose of ketamine (an anesthetic)added to morphine (an opioid) contributes to reducing pain intensity during open wound care procedure (WCP)in patients who have had a traumatic injury and are in an Intensive Care Unit. Patients will be randomized to receive morphine plus saline (a placebo) or morphine plus ketamine before the WCP. The second time the patient is scheduled for WCP (no less than 24 hours), patients... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/25/2024
Locations: University of California San Francisco, San Francisco, California +1 locations
Conditions: Wound Care, Pain Intensity, Hyperalgesia, Nausea, Vomiting, Hallucinations
Register for Updates
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
NCT04199468
Completed
The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects, and characterize the interactive effects of ketamine and THC on various electrophysiological (EEG), cognitive, and behavioral outcomes.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/21/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Cannabis, Ketamine
Register for Updates
Ketamine & Crisis Response Plan for Suicidal Ideation in the ED
NCT05696691
Recruiting
The goal of this randomized pilot trial is to assess the feasibility of administering a combination of 100mg intramuscular (IM) ketamine and Crisis Response Plan (a short psychosocial intervention) for patients with acute suicidality in the context of the Emergency Department setting. This study will assess a combination of a pharmacologic intervention and a psychosocial one. The pharmacologic intervention is a one-time dose of 100mg ketamine delivered intramuscularly (IM) while the patient is i... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: University Hospital, San Antonio, Texas
Conditions: Suicide
Register for Updates
Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
NCT05233566
Completed
This protocol describes a feasibility trial that will evaluate the feasibility of conducting a full-scale phase 3 trial testing the hypothesis that a postoperative sustained, low-dose ketamine infusion can prevent postoperative depressive symptoms when administered to a targeted population of neurosurgical patients with a history of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Postoperative Depression
Register for Updates
Ketamine as a Supplement to Local Anesthesia for Minor Procedures
NCT06284473
Recruiting
This trial is a double-blind randomized controlled clinical trial of adults and children (ages 7 to less than 70 years). Patients who present to the ED and who undergo minor bedside procedures that require local anesthesia will be divided into two groups: The first group will be treated with 0.7 mg/kg intranasal ketamine as well as standard local anesthesia for the procedure (treatment cohort). The second group will be treated with a volume-based dose of intranasal saline solution as well as sta... Read More
Gender:
ALL
Ages:
Between 7 years and 70 years
Trial Updated:
03/13/2024
Locations: Loyola University Medical Center, Maywood, Illinois
Conditions: Pain, Procedural, Minor Laceration, Abscess
Register for Updates
Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD
NCT06036511
Withdrawn
The goal of this clinical trial is to learn about the effects of Ketamine Assisted Psychotherapy \[KAP\] on individuals with Post Traumatic Stress Disorder \[PTSD\]. The main questions it aims to answer are: 1. Does KAP improve symptoms of PTSD? 2. What changes in brain network connectivity are seen with KAP?
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/08/2024
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: PTSD
Register for Updates